

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION

Reference is made to the announcement of the Company dated May 13, 2026 in relation to the purchase of wealth management products under the SPDB Wealth Management Product Agreements (the “**Announcement**”). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company would like to provide the following supplemental information to the Announcement.

PURCHASE OF WEALTH MANAGEMENT PRODUCTS

During the period from April 28, 2026 to May 13, 2026, the Company purchased seven wealth management products under the SPDB Wealth Management Product Agreements.

As the transactions contemplated under the SPDB Wealth Management Product Agreements are conducted with the same bank and are of similar nature within a 12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As at the time of purchase of wealth management product under the SPDB Wealth Management Product Agreement No. 3 on April 30, 2026, as one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreement No. 3 (calculated on an aggregation basis with the SPDB Wealth Management Product Agreement No. 1 and the SPDB Wealth Management Product Agreement No. 2) exceeded 5% but all of the applicable percentage ratios were less than 25%, the purchase of wealth management product under the SPDB Wealth Management Product Agreement No. 3 therefore constituted a discloseable transaction of the Company under Chapter 14 of the Listing Rules, to which the reporting and announcement requirements under the Listing Rules first arose. Accordingly, instead of reporting the purchase of all wealth management products under the SPDB Wealth Management Product Agreements in one announcement by way of publication of the Announcement on May 13, 2026, the Company should have complied with the reporting and announcement requirements on April 30, 2026, May 6, 2026, May 11, 2026 and May 13, 2026 for the purchase of wealth management products under the relevant SPDB Wealth Management Product Agreements conducted on the respective dates. Regrettably, the Company acknowledges that such compliance with the Listing Rules has been delayed due to its inadvertent oversight in monitoring the total balance of wealth management products with a single counterparty. To prevent the re-occurrence of similar incidents in the future, the Company will implement remedial measures, details of which are set out under “Remedial Measures to be taken by the Company” in this announcement.

REMEDIAL MEASURES TO BE TAKEN BY THE COMPANY

The Company understands that it should have informed the Stock Exchange and published an announcement as soon as possible in accordance with Rule 14.34 of the Listing Rules as and when the obligation for the purchase of wealth management products under the SPDB Wealth Management Product Agreements arose. The Company deeply regrets its non-compliance with the Listing Rules, but the Company would like to stress that such non-compliance was inadvertent and unintentional, and the Company had no intention to withhold any information in relation to the purchase of wealth management products under the SPDB Wealth Management Product Agreements from disclosure.

In order to prevent the occurrence of similar incidents in the future, the Company has taken or will take the following remedial measures:

- (1) The Company has issued an internal memo to all Directors, relevant department heads and relevant employees of the Group that the notifiable transaction requirements under Chapter 14 of the Listing Rules, in particular relating to the purchase of wealth management products, must be strictly complied with, and they shall keep the Company informed of any transactions which may involve disclosure and/or Shareholders’ approval requirements under Chapter 14 of the Listing Rules;
- (2) The Company will enhance the established wealth management product control list with respect to wealth management products, with details updated from time to time on an as-needed basis (and in any event at least monthly), including the subscription or redemption dates, the amounts subscribed or redeemed, the interests earned, the outstanding balances of the investments on an individual and aggregation basis, the size test calculations, as well as the maximum amount of the relevant wealth management products that can be purchased by the Group before the disclosure threshold is reached;

- (3) The Company will strengthen the communication, coordination and reporting arrangements between different departments of the Group in respect of the notifiable transaction requirements under Chapter 14 of the Listing Rules. Before entering into any potential notifiable transactions involving investments, the finance department of the Group will (i) review and verify the transaction details to ensure accuracy and regulatory alignment; (ii) review and monitor the aggregation of outstanding balances of the investments with the same institution within 12 months; (iii) verify the accuracy of the size tests calculation; (iv) assess and confirm whether the proposed transaction triggers any disclosure obligations and/or Shareholders' approval under Chapter 14 of the Listing Rules; and (v) report the proposed transaction and the Listing Rules implications, as well as submit the size tests calculation, to the management of the Company for approval. The relevant transaction can only be entered into after the Listing Rules implications have been assessed and confirmed by the management of the Company and the Company has complied with the applicable requirements under the Listing Rules;
- (4) The Company will invite its legal advisors and other professional advisors to provide internal training sessions regularly in respect of Chapter 14 of the Listing Rules for all Directors, relevant department heads and relevant employees of the Group to strengthen and reinforce their knowledge and understanding on the notifiable transaction requirements and disclosure obligations under Chapter 14 of the Listing Rules, highlighting the importance of complying with the Listing Rules, and their ability to identify potential issues at an early stage; and
- (5) The Company will consult external legal or other professional advisors as appropriate and necessary before entering into any potential notifiable transactions so as to ensure that the Directors' apprehension and interpretation of the Listing Rules are correct and that the Company timely complies with the relevant requirements under the Listing Rules. If necessary, the Company will also consult the Stock Exchange on the disclosure obligations of the potential notifiable transaction.

Going forward, the Company will continue to comply with the management procedures of its purchase of wealth management products and make appropriate disclosure in a timely manner to ensure compliance with the Listing Rules.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The People's Republic of China
May 19, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* For identification purpose only